These sessions are organised during the yearly meeting of the ESH and focus on problems on hypertensive patients seen in daily practice. The talks are given by experts but focus on having the material in an excellent educational format with many take-home messages.

20th European Meeting on Hypertension

 June 18-21, 2010 - Oslo, Norway

 Teaching Session 1

• Patient-centered genetics and genomics: Can we use it in clinical practice?
• Arterial Stiffness: what does it mean for our patients?
• Blood Pressure Should be Lowered <130/80 mmHg in High Risk Patients
• BP Targets (mmHg) by Treatment 

Teaching Session 2

• How to Treat Hypertension in Children and Adolescents
• How to Treat Hypertensin in Elderly Patients?
• Benefits and Risks of Sports in Hypertensive Patients

Teaching Session 3

• Resistant hypertension: a difficult case
• Antithrombotic drugs and hypertension: Indication or contra-indication
• Components of the POLYPILL
• Control of BP in the Population Is the Polypill the solution?

19th European Meeting on Hypertension

June 12-16, 2009 - Milan, Italy

Teaching Session 1 - Hypertension and other risk factors

• Diabetes and Hypertension
• Obesity and Hypertension
• Shall we continue using beta-blocking agents as first-line drugs in hypertension? Pro 
• Shall we continue using beta-blocking agents as first-line drugs in hypertension? Con

Teaching Session 2 - Management of Hypertension

• When to start treatment of high blood pressure
• Specific renin inhibitors
• How to improve compliance to antihypertensive therapy

• Round Table - Introduction: Do we need new antihypertensive drugs?

Teaching Session 3 - Blood pressure measurement

• New guidelines in HOME BP
• Central BP

• How to measure blood pressure in 2009

Teaching Seminars 2009

Interview with Prof. Denis Clement

The 18th Scientific Meeting of the European Society of Hypertension and the 22nd Scientific Meeting of the International Society of Hypertension

 June 14-19, 2008 - Berlin, Germany

Teaching Seminar 1 - Risk factors and hypertension in daily practice

• When to look for genetic influences in hypertensives
• Risk factors in hypertension: should we give antiplatelet drugs to all hypertensives? Should we give statins to all hypertensives?                                                       
• Do we need new antihypertensive drugs?

Teaching Seminar 2 - Secondary hypertension

• Hyperaldosteronism: should we check it in all hypertensive patients? Arguments pro      
• Diagnosis and management of hyperaldosteronism                                               
• Angioplasty for atherosclerotic renovascular disease                                                
• Pheochromocytoma

Teaching Seminar 3 - Treatment of hypertension in general and special conditions

• Treatment of HT in general and special conditions-about a difficult case
• Masked hypertension (isolated ambulatory hypertension)
• Hypertension in women - should they be treated differently?

XVII European Meeting on Hypertension 

June 17-21, 2007 - Milan, Itlay

 Teaching Seminar 1 - Special problems in hypertension

• Sex & the Heart                                                                                            
• Erectile dysfunction Therapeutic agents: Bad and Good 
• Obstructive sleep apnea syndrome (SAS): shall we check on all hypertensive (HT) patients?                                                                                                          
• Where is hypertension research going? 

Teaching Seminar 2 - Organ damage in hypertension

• Left Ventricular Hypertrophy-Role of echocardiogram
• Organ damage in hypertension Left Ventricular Hypertrophy-Role of ECG
• Organ damage in hypertension: Retinal Vessels
• Hypertension and the kidney
• Organ damage in hypertension-Systemic arteries

Teaching Seminar 3 - Detection and screening in hypertension

• Home BP monitoring 2007 Guidelines
• Shall we measure an ABI in all Hypertensive patients?
• New approaches to interfere with the RAS system: are they applicable in clinical practice?
• Renin-angiotensin aldosterone system (RAAS) acting drugs-pharmacological update

XVI European Meeting on Hypertension

June 12-15, 2006 - Madrid, Spain

Teaching Seminar 1 - WorkGroup 8

• Identification of total CV risk in the clinical practice. The European Approach
• Identification of total CV risk in the clinical practice. The USA Approach
• Do new markers of risk fit into the clinical assessment strategy?

Teaching Seminar 4

• How often and under which conditions do we see MA?
• What has hypertension to do with microalbuminuria?
• Does MA stay or can we change it?
• Does it help the prognosis when we reduce MA?

Teaching Seminar 6

• Trial of preventing hypertension (TROPHY): findings and implications
• Early resistance artery changes in essential hypertension
• The role of small arteries in hypertensive target organ damage
• Transient prehypertensive treatment and the progression of hypertension

Teaching Seminar 10

• Omics and cardiovascular disease or pathwayomics and cardiovascular disease
• Hypertension trials: have we been doing the right thing?
• Intervention on new mechanisms
• Arterial hypertension and public health

XV European Meeting on Hypertension

June 17-21, 2005 - Milan, Italy

Teaching Seminar 1

• Diagnosis and management of cardiac arrhythmias
• Mild to severe renal damage. Implication for cardiovascular risk and treatment
• Resistant hypertension: definition and management

Teaching Seminar 2

• Diagnosis and management of hyperaldosteronism
• Diagnosis and management of pheochromocytoma

Teaching Seminar 3

• How to improve compliance to antihypertensive therapy
• Hypertension in children
• Hypertension in the metabolic syndrome